BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Cui Y, Wang Q, Chang R, Zhou X, Xu C. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota. J Agric Food Chem. 2019;67:2754-2762. [PMID: 30798598 DOI: 10.1021/acs.jafc.9b00080] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
2 Bluemel S, Wang Y, Lee S, Schnabl B. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World J Gastroenterol 2020; 26(33): 4933-4944 [PMID: 32952340 DOI: 10.3748/wjg.v26.i33.4933] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Silva-Sperb AS, Moraes HA, de Moura BC, Alves BC, Bruch-Bertani JP, Azevedo VZ, Dall'Alba V. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. Trials 2019;20:580. [PMID: 31601229 DOI: 10.1186/s13063-019-3679-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2017;33:128-33. [PMID: 28257306 DOI: 10.1097/MOG.0000000000000349] [Cited by in Crossref: 70] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
5 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
6 Won SM, Park E, Jeong JJ, Ganesan R, Gupta H, Gebru YA, Sharma S, Kim DJ, Suk KT. The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. Int J Mol Sci 2021;22:8309. [PMID: 34361075 DOI: 10.3390/ijms22158309] [Reference Citation Analysis]
7 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
8 Fu ZD, Cui JY. Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep 2017;3:101-13. [PMID: 28983453 DOI: 10.1007/s40495-017-0087-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
9 Jin M, Kalainy S, Baskota N, Chiang D, Deehan EC, McDougall C, Tandon P, Martínez I, Cervera C, Walter J, Abraldes JG. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. Liver Int 2019;39:1437-47. [PMID: 30919578 DOI: 10.1111/liv.14106] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
10 Yu J, Zhang H, Chen L, Ruan Y, Chen Y, Liu Q. Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease. Front Cell Infect Microbiol 2021;11:698852. [PMID: 34568090 DOI: 10.3389/fcimb.2021.698852] [Reference Citation Analysis]
11 Inamine T, Schnabl B. Immunoglobulin A and liver diseases. J Gastroenterol 2018;53:691-700. [PMID: 29075899 DOI: 10.1007/s00535-017-1400-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
12 Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Front Med. 2018;12:645-657. [PMID: 30178233 DOI: 10.1007/s11684-018-0645-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
13 Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis. Hepatol Commun 2018;2:393-406. [PMID: 29619418 DOI: 10.1002/hep4.1165] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
14 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
16 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, Liu J, Mogavero S, Bosques-Padilla F, Abraldes JG, Vargas V, Tu XM, Yang L, Hou X, Hube B, Stärkel P, Schnabl B. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol 2020;72:391-400. [PMID: 31606552 DOI: 10.1016/j.jhep.2019.09.029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
18 Silva CBP, Elias-Oliveira J, McCarthy CG, Wenceslau CF, Carlos D, Tostes RC. Ethanol: striking the cardiovascular system by harming the gut microbiota. Am J Physiol Heart Circ Physiol 2021;321:H275-91. [PMID: 34142885 DOI: 10.1152/ajpheart.00225.2021] [Reference Citation Analysis]
19 Smirnova E, Puri P, Muthiah MD, Daitya K, Brown R, Chalasani N, Liangpunsakul S, Shah VH, Gelow K, Siddiqui MS, Boyett S, Mirshahi F, Sikaroodi M, Gillevet P, Sanyal AJ. Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity. Hepatology. 2020;72:271-286. [PMID: 32056227 DOI: 10.1002/hep.31178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
20 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
21 Gao B, Emami A, Nath S, Schnabl B. Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. Mol Nutr Food Res 2021;65:e2000023. [PMID: 32583604 DOI: 10.1002/mnfr.202000023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wang W, Xu AL, Li ZC, Li Y, Xu SF, Sang HC, Zhi F. Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice. Diabetes Metab J 2020;44:336-48. [PMID: 31950772 DOI: 10.4093/dmj.2019.0042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
23 Donovan SM. Introduction to the special focus issue on the impact of diet on gut microbiota composition and function and future opportunities for nutritional modulation of the gut microbiome to improve human health. Gut Microbes 2017;8:75-81. [PMID: 28282253 DOI: 10.1080/19490976.2017.1299309] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
24 Bluemel S, Wang L, Kuelbs C, Moncera K, Torralba M, Singh H, Fouts DE, Schnabl B. Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes 2020;11:265-75. [PMID: 30982395 DOI: 10.1080/19490976.2019.1595300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
25 Reuter B, Bajaj JS. Microbiome: Emerging Concepts in Patients with Chronic Liver Disease.Clin Liver Dis. 2020;24:493-520. [PMID: 32620285 DOI: 10.1016/j.cld.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Mendes BG, Schnabl B. From intestinal dysbiosis to alcohol-associated liver disease. Clin Mol Hepatol 2020;26:595-605. [PMID: 32911590 DOI: 10.3350/cmh.2020.0086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 Yi HW, Zhu XX, Huang XL, Lai YZ, Tang Y. Selenium-enriched Bifidobacterium longum protected alcohol and high fat diet induced hepatic injury in mice. Chin J Nat Med 2020;18:169-77. [PMID: 32245586 DOI: 10.1016/S1875-5364(20)30018-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
28 Ding Y, Yanagi K, Cheng C, Alaniz RC, Lee K, Jayaraman A. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. Pharmacol Res. 2019;141:521-529. [PMID: 30660825 DOI: 10.1016/j.phrs.2019.01.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
29 Lechner S, Yee M, Limketkai BN, Pham EA. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Dig Dis Sci 2020;65:897-905. [PMID: 32020359 DOI: 10.1007/s10620-020-06100-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
30 Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. Journal of Hepatology 2019;70:260-72. [DOI: 10.1016/j.jhep.2018.10.019] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 35.0] [Reference Citation Analysis]
31 Prokopienko AJ, Nolin TD. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. Expert Rev Clin Pharmacol 2018;11:71-82. [PMID: 28905671 DOI: 10.1080/17512433.2018.1378095] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
32 Barnes D, Park KT. Donor Considerations in Fecal Microbiota Transplantation. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0548-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
33 George AK, Singh M, Pushpakumar S, Homme RP, Hardin SJ, Tyagi SC. Dysbiotic 1-carbon metabolism in cardiac muscle remodeling. J Cell Physiol 2020;235:2590-8. [PMID: 31489638 DOI: 10.1002/jcp.29163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
34 Meroni M, Longo M, Dongiovanni P. Alcohol or Gut Microbiota: Who Is the Guilty? Int J Mol Sci. 2019;20. [PMID: 31540133 DOI: 10.3390/ijms20184568] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 19.5] [Reference Citation Analysis]
35 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
36 Milosevic I, Russo E, Vujovic A, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World J Gastroenterol 2021; 27(33): 5488-5501 [PMID: 34588747 DOI: 10.3748/wjg.v27.i33.5488] [Reference Citation Analysis]
37 Liu D, Huang J, Luo Y, Wen B, Wu W, Zeng H, Zhonghua L. Fuzhuan Brick Tea Attenuates High-Fat Diet-Induced Obesity and Associated Metabolic Disorders by Shaping Gut Microbiota. J Agric Food Chem 2019;67:13589-604. [DOI: 10.1021/acs.jafc.9b05833] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
38 Afshinnekoo E, Chou C, Alexander N, Ahsanuddin S, Schuetz AN, Mason CE. Precision Metagenomics: Rapid Metagenomic Analyses for Infectious Disease Diagnostics and Public Health Surveillance. J Biomol Tech 2017;28:40-5. [PMID: 28337072 DOI: 10.7171/jbt.17-2801-007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
39 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
40 Liu D, Wen B, Zhu K, Luo Y, Li J, Li Y, Lin H, Huang J, Liu Z. Antibiotics-induced perturbations in gut microbial diversity influence metabolic phenotypes in a murine model of high-fat diet-induced obesity. Appl Microbiol Biotechnol 2019;103:5269-83. [PMID: 31020379 DOI: 10.1007/s00253-019-09764-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
41 Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12:24-33. [PMID: 28550391 DOI: 10.1007/s12072-017-9798-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 14.5] [Reference Citation Analysis]